[
    {
        "type": "text",
        "text": "临床研究",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "21-三体综合征相关急性白血病21例报告",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "冉云霓，于洁，宪莹，温贤浩，郭玉霞，管贤敏，肖剑文重庆医科大学附属儿童医院，重庆400014",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "摘要：目的总结21-三体综合征(DS)相关急性白血病(AL)患儿的临床、实验室检查特点及疗效，提高诊疗水平。方法分析21例DS-AL患儿的临床表现、实验室检查、治疗及预后。结果 与非DS-AL相比,21例DS-AL患儿发病年龄1\\~5岁为主（占$8 5 . 7 \\%$ )，急性髓细胞白血病多见（占 $5 7 . 1 \\%$ )，乳酸脱氢酶 $\\cdot { > } 2$ 倍以上者较多（占 $6 1 . 9 \\%$ )；13例行心脏彩超检查10例异常（占$6 7 . 9 \\%$ )，复杂型先天性心脏病常见（占 $3 8 . 5 \\%$ );6例接受化疗，4例完全缓解（占 $6 6 . 7 \\%$ )，合并感染死亡2例，治疗相关死亡率$3 3 . 3 \\%$ ;2例减强度化疗者已分别无病生存21月及43月。结论DS-AL以急性髓细胞白血病多见，对化疗敏感，采用减强度化疗预后较好。",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "关键词：21-三体综合征;急性白血病;临床分析;减强度化疗",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Acute leukemia associated with Down syndrome: clinical analysis of 21 cases ",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "RAN Yunni, YU Jie,XIAN Ying,WEN Xianhao,GUO Yuxia,GUAN Xianmin,XIAO Jianwen Children's Hospital of Chongqing,Chongqing Medical University, Chongqing,400014 ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Abstract: ObjectiveTo summarize the clinical characteristics,laboratory findings and prognosis of patients withDown syndrome-relatedacute leukemia (DS-AL).Methods Theclinicaldata,laboratoryfidings,chemotherapyand prognosisof 1 children with DS-AL were analyzed.Results Mostof thechildren had disease onsetof leukemia at1to5 years of age $( 8 5 . 7 \\% )$ ！ and acute myeloid leukemia accounted for $5 7 . 1 \\%$ of these cases; $6 1 . 9 \\%$ of the patients had increased lactate dehydrogenase level by 2 folds or more. Of the 13 cases undergoing echocardiaography, 10 $( 6 7 . 9 \\% )$ showed abnormal findings,and complex congenital heart disease was common $( 3 8 . 5 \\%$ ). Six of the children received chemotherapy and complete remission was achieved in 4 cases; 2 patients died of infection,and the treatment-related mortality was $3 3 . 3 \\%$ . The 2 patients receiving reduced intensive chemotherapy have so far had event-free survival for 21 and 43 months.Conclusion Acute myeloid leukemiais the most common subtypeof DS-AL.Patients with DS-AL are sensitive to chemotherapy and the prognosis was favorable with reduced intensive chemotherapy. ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "ey words: Down syndrome; acute leukemia; clinical analysis; reduced intensive chemotheraj ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "21-三体综合征(Down syndrome,DS)是最常见的染色体病。DS发生急性白血病(acute leukemia,AL)等在内的血液系统疾病风险显著高于非DS人群，继发于DS的AL(DS-AL)患儿临床表现、实验室检查、治疗及预后与非DS-AL有很大差异，采用恰当治疗，DS-AL疗效高于非DS-AL。目前国内缺乏DS-AL较大样本报道,对中国人群疾病特点缺乏了解;由于存在误区，接受治疗的DS-AL也甚为少见。为提高DS-AL诊疗水平，收集2004年8月\\~2014年8月本院诊治21例DS-AL患儿的临床资料、实验室检查及治疗情况，报道如下。",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "1资料和方法",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "1.1一般资料",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "2004.08.01\\~2014.08.01本院收治DS-AL患儿21例，男8例，女13例。年龄4d到11岁3月（平均年龄",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "3.15岁，中位年龄1岁6月）,0\\~1岁组1例，1\\~5岁组17例， $> 5$ 岁组3例。所有患儿均有眼距宽、眼裂小、外眼角上斜、鼻梁低平等特殊面容及通贯掌、草履足等皮纹改变。发病时有发热8例，出血15例(均为皮肤出血）肝脾肿大16例(仅肝脏肿大3例，仅脾脏肿大1例，肝脾均肿大12例）、骨痛及黄疸各1例，所有患儿均无睾丸及中枢神经系统浸润表现",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "1.2 检查",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "初诊血常规(表1)：白细胞 $( \\mathrm { W B C } ) 2 . 4 { \\sim } 1 2 2 . 0 { \\times } 1 0 ^ { 9 } / \\mathrm { L }$ (平均值 $2 8 . 3 9 { \\pm } 3 4 . 1 7 { \\times } 1 0 ^ { 9 } / \\mathrm { L }$ ,中位值 $9 . 6 7 \\times 1 0 ^ { 9 } / \\mathrm { L }$ )，15例外周血可见幼稚细胞；血小板( $\\mathrm { P L T } ) 4 { \\sim } 7 7 { \\times } 1 0 ^ { 9 } / \\mathrm { L }$ (平均值$\\displaystyle 2 1 . 6 7 { \\pm } 1 6 . 9 1 { \\times } 1 0 ^ { 9 } / \\mathrm { L }$ ，中位数 $1 4 \\times 1 0 ^ { 9 } / \\mathrm { L }$ )；血红蛋白 $\\left( \\mathrm { H b } \\right)$ $3 2 { \\sim } 1 4 5 \\mathrm { g / L }$ (平均值 $7 4 . 0 5 { \\scriptstyle \\pm 2 8 . 8 7 ~ \\mathrm { g / L } }$ ，中位数 $7 4 \\ \\mathrm { g / L } \\$ ）",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "骨髓检查：骨髓细胞学及组织化学染色、结合流式细胞术免疫分型后按FAB分型(表2)：急性淋巴细胞白血病(ALL)6例，急性髓细胞性白血病(AML)12例，3例为形态学不能分型结合流式细胞术确诊为急性混合细胞性白血病(MAL)。16例做骨髓染色体核型：12例仅有21三体;4例AML合并其它核型异常,分别为： $\\textcircled{1} 4 9$ XX, der(3)t(1;3) $( \\mathbf { q } 3 2 ; \\mathbf { q } 2 2 . 9 )$ ，del(6) (q13;q21), $+ 8$ ， $^ +$ 21, $+ 1 1$ $\\textcircled{2}$ 48,XX,-C, $+ 2 \\mathrm { G } / 4 7 , \\mathrm { X X , + G } ; \\textcircled { 3 } 4 9 , \\mathrm { X X }$ add(9) $( \\mathbf { p } 2 2 ) \\mathbf { x } 2$ ， $+ 1 1$ ,der(11;14)(q10;q10), $+ 2 0$ ,der(20;",
        "page_idx": 0
    },
    {
        "type": "table",
        "img_path": "images/6c8f1b4b41a0aceb82876416a48901db87cb1911b3780bd49a3f3ba67a6ca6cc.jpg",
        "table_caption": [
            "表1初诊血常规 Tab.1 Findings in routine blood tests at diagnosis "
        ],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td></td><td colspan=\"4\">Hb (g/L)</td><td colspan=\"3\">WBC count (x10/L)</td><td colspan=\"2\">PLT count (x10/L)</td></tr><tr><td></td><td>>110</td><td>90-110</td><td>60-90</td><td>30-60</td><td>>4</td><td>4-10</td><td><10</td><td><50</td><td><20</td></tr><tr><td>Cases (n)</td><td>2</td><td>3</td><td>7</td><td>9</td><td>3</td><td>8</td><td>10</td><td>9</td><td>12</td></tr><tr><td>Ratio</td><td>9.5%</td><td>14.3%</td><td>33.3%</td><td>42.9%</td><td>14.3%</td><td>38.1%</td><td>47.6%</td><td>42.9%</td><td>57.1%</td></tr></table></body></html>",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "22)(q10:q10), $^ { + 2 1 }$ (15)/47，XX， $+ 2 1$ (5）； $\\textcircled { 4 } 4 8 , \\mathrm { X Y , + 1 0 , + }$   \n$2 1 / 4 6 { , } \\mathrm { X Y }$ 。10例做白血病融合基因检测均未见异常。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "14例患儿行外周血染色体核型分析确诊DS(4例系家属口述，未见报告),7例骨髓染色体检查结合临床",
        "page_idx": 1
    },
    {
        "type": "table",
        "img_path": "images/101b4b2fd39cb5710b6efe55ea0a5eb99d453780bbbcf5a3c714f33727d56b8e.jpg",
        "table_caption": [
            "表2细胞学及免疫分型与发病年龄 Tab.2 Age at diagnosis and cytological and immunological phenotypes of the patients "
        ],
        "table_footnote": [],
        "table_body": "<html><body><table><tr><td>Age,morphology and immunophenotype</td><td></td><td><lyr (n)</td><td>1-5yr (n)</td><td>>5yr (n)</td><td>Total (n, %)</td></tr><tr><td rowspan=\"3\">ALL</td><td>ALL-L1</td><td>0</td><td>0</td><td>1</td><td rowspan=\"3\">6(28.6%)</td></tr><tr><td>ALL-L2</td><td>1</td><td>2</td><td>2</td></tr><tr><td>AML-M1</td><td>0</td><td>2</td><td>0</td></tr><tr><td rowspan=\"3\">AML</td><td>AML-M2a</td><td>0</td><td>5</td><td>0</td><td rowspan=\"3\">12 (57.1%)</td></tr><tr><td>AML-M5a</td><td>0</td><td>2</td><td>0</td></tr><tr><td>AML-M5b</td><td>0</td><td>1</td><td>0</td></tr><tr><td rowspan=\"4\">MAL</td><td>AML-M7</td><td>0</td><td>2</td><td>0</td><td rowspan=\"4\"></td></tr><tr><td>AML+pre-B-ALL</td><td>0</td><td>2</td><td>0</td></tr><tr><td>C-B-ALL+AML</td><td>0</td><td>1</td><td>0</td></tr><tr><td>Total (n, %)</td><td>1 (4.7%)</td><td>17 (81.0%)</td><td>3 (14.3%)</td></tr></table></body></html>",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "表现确诊DS。可供分析的外周血染色体报告10例均为标准型。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "肝功检查有1例胆红素增加，5例谷丙转氨酶增加，18例有乳酸脱氢酶(LDH)增加 $( 2 6 2 - 5 0 5 0 \\mathrm { U / L }$ ，平均值$1 0 9 2 . 2 2 \\pm 1 0 7 2 . 1 1 \\ \\mathrm { U } / \\mathrm { I }$ 、中位值 ${ 8 4 9 } ~ \\mathrm { U / L }$ ，参考值110\\~$3 3 0 \\mathrm { U / L } \\$ 。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "13例行心脏彩超检查，10例有先天性心脏病。包括单纯室间隔缺损(ventricular septal defect,VSD)2例、房间隔缺损(atrial septaldefect,ASD)1例及卵圆孔未闭2例；5例有2种及以上先天性心脏病，包括3例VSD合并动脉导管未闭(patent ductusarteriosus,PDA),1例ASD合并PDA,1例ASD、VSD、PDA合并主动脉缩窄。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.3 治疗 ",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "6例患儿接受至少一个疗程化疗(4例AML,1例ALL，1例MAL)。2例AML患儿接受DAE方案化疗达到完全缓解(completeremission,CR)未继续治疗，失访；AML及ALL各1例分别给予DAE、VDLP方案化疗，因明显骨髓抑制合并严重感染死亡；AML和MAL各1例接受减强度规范化疗达到持续CR,分别无病生存21月及43月[2]。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2结果",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "本组患儿均有DS典型面容且及皮纹改变，结合染色体检查确诊DS,骨髓检查均确诊为AL。男女性别比0.615:1,女性多见。AL以发热、贫血、出血及浸润为主要表现，无睾丸及中枢神经系统浸润；发病年龄1-5岁组为主，占 $8 5 . 7 \\%$ （表2)。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "所有患儿均血小板减少， $\\mathrm { P L T } { < } 2 0 { \\times } 1 0 ^ { 9 } / \\mathrm { L }$ 为主，占$5 7 . 1 \\%$ 。19例有贫血，占 $9 0 . 5 \\%$ ,9例为重度贫血，占$4 2 . 9 \\%$ 。白细胞计数异常者为主，其中白细胞降低3例、增高10例、正常者8例,分别占 $1 4 . 3 \\% . 4 7 . 6 \\%$ 及 $3 8 . 1 \\%$ ·15例外周血可见异常细胞，占 $7 1 . 4 \\%$ （表1）。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "骨髓检查6例ALL（占 $2 8 . 6 \\%$ ),12例AML（占 ",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "$5 7 . 1 \\%$ ),3例MAL（占 $1 4 . 3 \\%$ ),AML多见。AML以AML-M2a型为主，占 $4 1 . 7 \\%$ 。1例AML-M2a型系骨髓异常增生综合征(myelodysplastic syndrome,MDS)转化。ALL发病时 $^ { < 1 }$ 岁1例，1\\~5岁2例， $> 5$ 岁3例，AML及MAL发病年龄均1\\~5岁(表2)。除21-三体外骨髓染色体有其它异常者均为AML且系复杂核型。白血病融合基因检查均未见异常。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "21例患儿有18例LDH增加，占 $8 5 . 7 \\%$ ，其中 $> 2$ 倍以上16例(占 $6 1 . 9 \\%$ )。13例行心脏彩超检查10例异常者(占 $6 7 . 9 \\%$ ),以复杂型先天性心脏病为主（占 $3 8 . 5 \\%$ )。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "接受化疗的6例患儿有4例CR（占 $6 6 . 7 \\%$ )，2例因骨髓抑制合并严重感染死亡，治疗相关死亡率(treat-relatedmortality,TRM) $3 3 . 3 \\%$ 。2例接受减强度规范治疗持续CR。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "3讨论",
        "text_level": 1,
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "DS系出生时21-染色体为三体所致，是最常见的染色体病，以典型的特殊面容和认知损害、高发心脏及免疫缺陷等先天畸形为特征[。本组患儿均有DS典型面容且及皮纹改变,结合染色体检查确诊为DS,骨髓检查确诊AL,本组患儿均DS-AL诊断明确",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "研究发现 ${ } ^ { [ 3 ] } \\mathrm { D } \\mathrm { S }$ 患儿容易发生多种血液系统疾病如巨红细胞症、短暂性血小板计数异常、暂时性骨髓增殖性疾病、MDS等。国外资料表明[4DS-AL发病率 $2 . 7 \\%$ 为非DS儿童14\\~30倍。非DS-AL患儿以ALL为主，而DS-AL则以AML常见,本组病例AML者12例,ALL者6例，符合DS-AL发病特征。目前国内没有DS-AL发病率的资料。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "文献报道5无论DS或非DS人群，AL发病均以发热、贫血、出血、肝脾肿大等浸润为主要表现,血常规多表现为血小板及血红蛋白减少，白细胞计数增高及外周血发现异常细胞多见，与本组病例一致。有报道建议DS患儿可考虑定期骨髓检查争取早期发现AL[3,但何时及何种情况下骨髓检查尚无结论。LDH增高可能与肿瘤性疾病相关，本组患儿LDH多大于正常值2倍以上，故LDH增加可考虑作为DS行骨髓检查的指征。文献报道DS合并MDS机会较高，本组患儿仅1例患儿有MDS病史，可能与样本量较少有关，也提示怀疑合并血液系统疾病拟行骨髓检查时应同时做骨髓活检。本组患儿中可供分析的外周血染色体报告10例均为标准型，提示标准型DS发生AL的可能性较大。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "DS-AML发病率为非DS-AML的150倍。由于DS-AML有其独特的生物学和临床特征，故WHO-2008分类系统将其定义为一种独特的AML亚类，其临床特点包括[8：诊断时年龄一般 $\\lvert \\lvert \\lvert \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\langle \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\lvert \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\lvert \\langle \\lvert \\lvert \\lvert \\langle \\lvert \\lvert \\lvert \\langle \\lvert \\lvert \\lvert \\langle \\lvert \\lvert   \\langle \\lvert \\lvert  \\lvert \\langle \\lvert \\lvert  \\lvert  \\lvert \\langle \\lvert \\lvert  \\lvert \\lvert  \\langle \\lvert  \\lvert  \\lvert \\lvert \\langle  \\lvert \\lvert  \\lvert \\lvert \\lvert  \\langle   \\lvert \\lvert \\lvert  \\lvert        $ 岁、多无中枢神经系统浸润证据、既往多有MDS病史等，与本组患儿特征一致。本组患儿以女性居多，白细胞计数增高多见，细胞形态学分型AML-M2a最多，但文献报道DS-AML无明显性别差异、白细胞计数较低、FAB分型多为M7和未分型AML[9-10],考虑与本组样本量小有关。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "DS-ALL占DS-AL约1/3,发病率为非DS-ALL的10\\~20倍[1]。与DS-AML相比,DS-ALL多发生于1\\~10岁、婴儿白血病少见[8]。本组DS-ALL年龄也无明显特点，表明与非DS组相比，DS-ALL临床表现特异性不显著[3]。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "21-三体染色体对阿糖胞苷等药物代谢有影响且DS-AL白血病细胞多存在GATA1突变，故DS-AL患儿对多种化疗药物尤其是阿糖胞苷、甲氨蝶呤及蒽环类敏感[12-13],DS-AL积极治疗预后较好。但药物副作用尤其是严重骨髓抑制常增加感染机会，而DS多合并先天性心脏病，故患儿多不能耐受高强度化疗。高强度化疗相关死亡是DS-AL预后不良的主要因素[14],本组接受治疗的6例患儿中4例系采用标准化疗方案，2例因严重感染死亡。目前DS-AL多采用减强度的化疗方案[15],降低治疗相关死亡率而不影响无病生存率。尤其是DS-AML的预后明显好于非DS(4年无病生存率分别为$8 8 \\%$ 和 $4 2 \\%$ $P { < } 0 . 0 0 1 )$ [9-10]。也有研究表明[16],与标危化疗方案相比，DS-ALL患儿接受高危化疗方案后预后更好，通过积极处理强化治疗相关的不良反应和改善支持治疗，可将DS-ALL患儿的EFS提高到接近 $80 \\%$ ，与非DS持平。本组2例患儿(AML和MAL各1例)经减强度化疗均达到CR,治疗相关副作用轻微,均无病生存[2],表明采用恰当的治疗，DS-AL预后良好。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "由于认识不足，国内仅有DS-AL个案报道，更缺乏疗效及预后相关资料，本文首次较大样本报道DS-AL尤其是治疗、预后。发现DS-AL尤其是DS-AML与非DS-AL临床特点、治疗方案及疗效均存在一定差异，应积极鼓励DS-AL尤其是DS-AML患儿接受以减低强度为主的化疗。",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "参考文献：",
        "text_level": 1,
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "[1]Pikora TJ,Bourke J,Bathgate K,et al.Health conditions and their impact among adolescents and young adults with Down syndrome [J].PLOS One,2014,9(5): e96868.   \n[2]冉云霓,于 洁,宪 莹,等.减低强度化疗治疗儿童21-三体综合征合并 急性白血病二例并文献复习[J].中华血液学杂志,2014,35(12): 1119-21.   \n[3]Manivannan P,Prasaad PR,Kar R,et al.Down syndrome with different hematological manifestations:a short series of 3 cases with review of literature[J].Indian J Hematol Blood Transfus, 2013,29(1): 31-4.   \n[4]Maloney KW,Taub JW,Ravindranath Y,et al.Down syndrome preleukemia and leukemia[J].Pediatr Clin North Am,2015,62(1): 121-37.   \n[5]Davis KL,Marina N,Arber DA,et al. Pediatric acute myeloid leukemia as classified using 2Oo8 WHO criteria:a single-center experience[J].AmJClin Pathol,2013,139(6): 818-25.   \n[6]Lam GK,Leung AW,Ha SY,et al.Acute leukemia in down syndrome children in Hong Kong: retrospective review[J].JPediatr Hematol Oncol,2016,38(2): 102-6.   \n[7]Khan I, Malinge S, Crispino J. Myeloid leukemia in Down syndrome [J].Crit Rev Oncog,2011,16(1/2): 25-36.   \n[8]Arico M,Ziino O,Valsecchi MG,et al.Acute lymphoblastic leukemia and Down syndrome:presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP)[J].Cancer,2008，113(3): 515-21.   \n[9]Lange BJ,Kobrinsky N, Barnard DR,et al. Distinctive demography, biology，and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome:children's cancer group studies 2861 and 2891[J].Blood,1998,91(2): 608-15.   \n[10]Li MJ,Lee NC,Yang YL,et al. Long-term outcome for Down syndrome patients with hematopoietic disorders [J].J Form Med Assoc,2016,115(2): 94-9.   \n[11]Tigay JH.A comparison of acute lymphoblastic leukemia in Down syndrome and non-Down syndrome children: the role of trisomy 21 [J].J Pediatr Oncol Nurs,2009,26(6): 362-8.   \n[12]Ono R,Hasegawa D,Hirabayashi S,et al.Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children[J].Eur J Pediatr,2015,174(4): 525-31.   \n[13]Hefti E,Blanco JG.Anthracycline-Related cardiotoxicity in patients with acute myeloid leukemia and down syndrome:a literature review[J].Cardiovasc Toxicol,2016,16(1):5-13.   \n[14]Malinge S,Izraeli S,Crispino JD.Insights into the manifestations, outcomes,and mechanisms of leukemogenesis in Down syndrome [J].Blo0d,2009,113(12): 2619-28.   \n[15]Ravindranath Y,Chang M, Steuber CP,et al. Pediatric oncology group (POG) studies of acute myeloid leukemia(AML):a review of four consecutive childhood AML trials conducted between 1981 and 2000[J].Leukemia,2005,19(12):2101-16.   \n[16] O'rafferty C,Kelly J,Storey L,et al.Child and adolescent Down syndrome-associated leukaemia: the Irish experience[J].Ir J Med Sci,2015,184(4): 877-82. (编辑：经媛) ",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 3
    }
]